Guardant Health Stock Surges 30% on Strong Earnings and Raised Guidance
Guardant Health shares skyrocketed 30% following a robust third-quarter earnings report and upward revision of full-year revenue projections. The precision oncology firm reported $265.2 million in Q3 revenue, marking a 39% year-over-year increase, with its cancer screening segment showing particular strength.
Positive free cash FLOW arrived ahead of schedule, while the net loss of $0.74 per share beat analyst expectations. The company now anticipates full-year revenue between $965-$970 million, up from previous guidance of $915-$925 million, signaling accelerating growth across its oncology and biopharma divisions.